Our Mission
At Elpida BioPharm, we draw our name and our inspiration from the ancient Greek word “ελπίδα” (elpí̱da), meaning hope. Hope is at the very heart of everything we do: from pioneering fundamental discoveries in biomedical science to translating those breakthroughs into real-world therapies that bring life-changing possibilities to patients, especially those battling cancer.
Building on rigorous academic research and collaborations with leading institutions, our multidisciplinary team is committed to bridging the gap between the laboratory bench and the patient’s bedside. We harness cutting-edge platforms—ranging from precision cytokine delivery for immunotherapy to targeted hormone-degradation strategies—to develop next-generation therapies that not only attack disease at its root but also restore the hope and dignity every patient deserves. Driven by empathy and scientific excellence, our mission is to:
Innovate with purpose: Advance novel drug candidates through streamlined pre-clinical and clinical pathways, focusing first on those most in need.
Translate with urgency: Move promising discoveries rapidly into human trials, accelerating timelines while upholding the highest standards of safety and efficacy.
Empower with compassion: Partner with patients, caregivers, and healthcare providers to ensure our treatments not only extend life but also enhance its quality.
At Elpida BioPharm, we believe that every breakthrough, no matter how small, can ignite hope where it’s needed most. Our ultimate goal is to transform hope into healing, one patient at a time.
Management Team
Alexey V. Yaremenko, Ph.D.
Chief Executive Officer (CEO) & Co-Founder
Dr. Alexey Yaremenko is a molecular biologist and biomedical entrepreneur who leads Elpida BioPharm’s strategic vision and scientific direction. With a Ph.D. in molecular biology and extensive training in nanomedicine, gene therapy and precision drug delivery (Fulbright Fellow at Harvard Medical School), he has pioneered mRNA-based therapeutics and engineered nanocarriers for cancer immunotherapy and regenerative medicine. Alexey has authored numerous high-impact publications, served as Guest Editor on biomedical frontier technologies, and been honored with awards such as the Fulbright Fellowship and the Nobel Laureate J. Alferov Young Scientist Award. As CEO, he combines deep research expertise with business acumen to translate cutting-edge science into life-saving treatments.
Nadezhda A. Pechnikova, M.Sc.
Chief Scientific Officer (CSO) & Co-Founder
Nadezhda Pechnikova is a multidisciplinary biologist and bioinformatician driving Elpida BioPharm’s discovery pipeline. She holds a Master’s in Host–Microbe Interactions (University of Thessaly) and conducts regenerative-medicine research at Aristotle University, focusing on tissue engineering and biomaterials. Nadezhda specializes in microbiology, cancer therapy, and in experimental pharmacology for novel therapeutic compounds. She also advises investment firms on clinical trial opportunities in public pharmaceutical companies, bridging data-driven insights with translational research. As CSO, she oversees preclinical development and microbiological strategy to advance Elpida’s hope-driven mission.